{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:01:22Z","timestamp":1776038482098,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,21]],"date-time":"2013-07-21T00:00:00Z","timestamp":1374364800000},"content-version":"vor","delay-in-days":1328,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.curtheres.2009.11.001","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T09:49:28Z","timestamp":1264499368000},"page":"405-420","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder"],"prefix":"10.1016","volume":"70","author":[{"given":"Franklin","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neila","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2009.11.001_bib1","first-page":"30","article-title":"The overactive bladder and quality of life","volume":"50","author":"Epstein","year":"2005","journal-title":"Int J Fertil Womens Med."},{"key":"10.1016\/j.curtheres.2009.11.001_bib2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0022-5347(05)00313-7","article-title":"Overactive bladder: A better understanding of pathophysiology, diagnosis and management","volume":"175","author":"Wein","year":"2006","journal-title":"J Urol."},{"key":"10.1016\/j.curtheres.2009.11.001_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology."},{"key":"10.1016\/j.curtheres.2009.11.001_bib4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study [published correction appears in BJU Int. 2001;88:807]","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int."},{"key":"10.1016\/j.curtheres.2009.11.001_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol."},{"key":"10.1016\/j.curtheres.2009.11.001_bib6","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1532-5415.2000.tb04744.x","article-title":"Urinary incontinence: Does it increase risk for falls and fractures?","volume":"48","author":"Brown","year":"2000","journal-title":"J Am Geriatr Soc."},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2009.11.001_bib7","first-page":"S574","article-title":"Comorbidities associated with overactive bladder","volume":"6","author":"Brown","year":"2000","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.curtheres.2009.11.001_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0094-0143(21)00523-1","article-title":"Epidemiology and psychosocial aspects of incontinence","volume":"22","author":"Diokno","year":"1995","journal-title":"Urol Clin North Am."},{"key":"10.1016\/j.curtheres.2009.11.001_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1185\/030079904125003593","article-title":"The wet patient: Understanding patients with overactive bladder and incontinence","volume":"20","author":"Serels","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.curtheres.2009.11.001_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1046\/j.1464-410X.2002.02963.x","article-title":"The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women","volume":"90","author":"van der Vaart","year":"2002","journal-title":"BJU Int."},{"key":"10.1016\/j.curtheres.2009.11.001_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/01.gco.0000183529.26352.52","article-title":"Overactive bladder: Epidemiology and social impact","volume":"17","author":"Tubaro","year":"2005","journal-title":"Curr Opin Obstet Gynecol."},{"key":"10.1016\/j.curtheres.2009.11.001_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0090-4295(03)00009-8","article-title":"Estimated economic costs of overactive bladder in the United States","volume":"61","author":"Hu","year":"2003","journal-title":"Urology."},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2009.11.001_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjmed.2005.12.014","article-title":"Management of overactive bladder and urge urinary incontinence in the elderly patient","volume":"119","author":"Erdem","year":"2006","journal-title":"Am J Med."},{"key":"10.1016\/j.curtheres.2009.11.001_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11934-007-0032-6","article-title":"How to choose the initial drug treatment for overactive bladder","volume":"8","author":"MacDiarmid","year":"2007","journal-title":"Curr Urol Rep."},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2009.11.001_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjmed.2005.12.011","article-title":"Using anticholinergics to treat overactive bladder: The issue of treatment tolerability","volume":"119","author":"Staskin","year":"2006","journal-title":"Am J Med."},{"key":"10.1016\/j.curtheres.2009.11.001_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.curtheres.2009.11.001_bib17","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol."},{"key":"10.1016\/j.curtheres.2009.11.001_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int."},{"key":"10.1016\/j.curtheres.2009.11.001_bib20","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol."},{"key":"10.1016\/j.curtheres.2009.11.001_bib21","series-title":"SAS\/Stat User's Guide Version 6","first-page":"1221","year":"1990"},{"key":"10.1016\/j.curtheres.2009.11.001_bib22","series-title":"MedDRATM version 3.2. Medical Dictionary for Regulatory Activities","year":"2000"},{"key":"10.1016\/j.curtheres.2009.11.001_bib23","first-page":"351","article-title":"On the combination of two-sample tests of Wilcoxon","volume":"37","author":"Van Elteren","year":"1960","journal-title":"Bull Int Stat Inst."},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2009.11.001_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1464-410X.2005.05651.x","article-title":"Role of muscarinic receptor antagonists in urgency and nocturia","volume":"96","author":"Michel","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.curtheres.2009.11.001_bib25","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","article-title":"Guidelines for Industry: Statistical Principles for Clinical Trials (E9)","year":"1998"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X09001027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X09001027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:21:18Z","timestamp":1634761278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X09001027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0011393X09001027"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2009.11.001","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}